Navigation Links
Researchers join forces to cure deadly childhood disease
Date:5/3/2011

ST. LOUIS -- The Center for World Health and Medicine at Saint Louis University and the Institute for OneWorld Health have established a joint research agreement to develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5.

Each year more than two million children in developing countries die from diarrheal diseases, which are caused by a wide range of bacterial, parasitic and viral pathogens. These organisms can be particularly virulent in the developing world, which is plagued by poor sanitation, unclean water, malnutrition and a lack of knowledge about how to prevent the illnesses.

Diarrhea is frequently a symptom of another disease, such as cholera and rotavirus, and turns deadly in children who rapidly lose body fluids, become severely dehydrated and go into shock.

"When children in St. Louis, Mo., develop severe diarrhea and become lethargic, their parents take them to the emergency room, where they are given IV fluids," said Peter Ruminski, executive director of the Center for World Health and Medicine.

"Places like rural Sub-Saharan Africa or Haiti lack adequate sanitation and access to clean water and don't have the same infrastructure that we have. Families there are not as readily able to hop in their vehicles, drive to the hospital and get hooked up to an IV to replenish vital body fluids. So if we can come up with a therapy to reduce fluid loss and get children through the acute attack phase of their diarrheal illness, we'll have an immediate effect on the number of children who die. Our goal is to save lives."

The collaboration between the Center for World Health and Medicine and the Institute for OneWorld Health (iOWH) aims to develop safe and effective anti-secretory drugs, which inhibit the loss of fluid in the intestine regardless of the root cause of the problem. These drugs are intended to be used as an adjunct to oral rehydration therapy.

"The Institute for OneWorld Health is committed to finding treatments for cholera and other diarrheal diseases that claim the lives of so many infants and children around the world," said Richard Chin, M.D., iOWH CEO. "This partnership will bring us closer to saving millions of children who would otherwise die from treatable diseases."

Under the agreement, the Center for World Health and Medicine will provide expertise in medicinal chemistry and pharmacology to identify potential anti-secretory drug candidates for future development.

Jon Jacobsen, Ph.D., director of chemistry at SLU's Center for World Health and Medicine, is leading the effort along with Brian Bond, Ph.D., the Center's director of pharmacology, and will closely collaborate with the medicinal chemistry group at the University of Missouri-St. Louis, led by John Walker, Ph.D.


'/>"/>

Contact: Nancy Solomon
solomonn@slu.edu
314-977-8017
Saint Louis University
Source:Eurekalert

Related biology news :

1. NC State researchers get to root of parasite genome
2. Researchers find animal with ability to survive climate change
3. Researchers find an essential gene for forming ears of corn
4. Researchers note differences between people and animals on calorie restriction
5. Researchers study acoustic communication in deep-sea fish
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Researchers study how pistachios may improve heart health
8. UI researchers find potentially toxic substance present in Chicago air
9. Researchers develop new self-training gene prediction program for fungi
10. Case Western Reserve University researchers track Chernobyl fallout
11. Childrens National researchers develop novel anti-tumor vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a ... its financial results for the fourth quarter and fiscal year ... Total sales in the fourth quarter ... by 13.6% in USD terms to $77.6 million from $68.3 ... Gross profit increased by 13.3% to $46.8 million from $41.3 ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
Breaking Biology Technology: